Citadel Advisors
SGYP

Citadel Advisors’s Synergy Pharmaceuticals, Inc Common Stock SGYP Stock Holding History

Citadel Advisors’s Portfolio SGYP Stock Details SGYP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-145,400
Closed -$17K – 10276
2018
Q4 		$17K Sell
145,400
-10,200
-7% -$6.69K ﹤0.01% 8811
2018
Q3 		$265K Sell
155,600
-22,700
-13% -$40.6K ﹤0.01% 7782
2018
Q2 		$310K Buy
178,300
+37,500
+27% +$64.8K ﹤0.01% 7160
2018
Q1 		$258K Buy
140,800
+43,000
+44% +$90.8K ﹤0.01% 6972
2017
Q4 		$218K Buy
97,800
+29,100
+42% +$72.3K ﹤0.01% 6986
2017
Q3 		$199K Buy
68,700
+12,300
+22% +$42K ﹤0.01% 6701
2017
Q2 		$251K Sell
56,400
-28,100
-33% -$116K ﹤0.01% 6203
2017
Q1 		$394K Buy
84,500
+18,000
+27% +$104K ﹤0.01% 5439
2016
Q4 		$405K Buy
66,500
+31,200
+88% +$163K ﹤0.01% 5232
2016
Q3 		$195K Buy
+35,300
New +$165K ﹤0.01% 6328

Other funds holding SGYP

TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Citadel Advisors's SGYP Position: Q1 2019 in Review

Citadel Advisors sold out of Synergy Pharmaceuticals, Inc Common Stock (SGYP) in Q1 2019, closing a stake of 547,822 shares — an estimated $62K sold.

Citadel Advisors first reported a position in SGYP in Q1 2014 and held it in 18 quarters. The position peaked at $27.5M in Q1 2017. 12 funds tracked by Wall St. Rank hold SGYP as of Q1 2019.

  • Citadel Advisors reported no remaining Synergy Pharmaceuticals, Inc Common Stock position as of Q1 2019 after selling out during the quarter.
  • Citadel Advisors sold 547,822 Synergy Pharmaceuticals, Inc Common Stock shares in Q1 2019, an estimated $62K.
  • Citadel Advisors first reported a position in Synergy Pharmaceuticals, Inc Common Stock in Q1 2014 and held it in 18 quarters.
  • Citadel Advisors's Synergy Pharmaceuticals, Inc Common Stock position peaked at $27.5M in Q1 2017.
  • 12 funds tracked by Wall St. Rank held Synergy Pharmaceuticals, Inc Common Stock as of Q1 2019.

Based on Citadel Advisors's 13F filing for Q1 2019, filed 15 May 2019.